Candida chorioretinitis and endophthalmitis

References

• Pappas P. Invasive candidasis. Infect. Dis. Clin. North Am.20(3), 485–606 (2006).
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Shivaprakash MR, Singh R et al. Fungal endophthalmitis: fourteen years’ experience from a center in India. Retina28(10), 1400–1407 (2008).
   PubMed Web of Science ®Google Scholar
• Feman SS, Nichols JC, Chung SM, Theobald TA. Endophthalmitis in patients with disseminated fungal disease. Trans. Am. Ophthalmol. Soc.100, 67–70; discussion 70–61 (2002).
   PubMedGoogle Scholar
• Chen YC, Chang SC, Luh KT, Hsieh WC. Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J. Antimicrob. Chemother.52(1), 71–77 (2003).
   PubMed Web of Science ®Google Scholar
• Donahue SP, Greven CM, Zuravleff JJ et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology101(7), 1302–1309 (1994).
   PubMed Web of Science ®Google Scholar
• Shah CP, McKey J, Spirn MJ, Maguire J. Ocular candidiasis: a review. Br. J. Ophthalmol.92(4), 466–468 (2008).
   PubMed Web of Science ®Google Scholar
• Parke DW 2nd, Jones DB, Gentry LO. Endogenous endophthalmitis among patients with candidemia. Ophthalmology89(7), 789–796 (1982).
   PubMed Web of Science ®Google Scholar
• Narang S, Gupta A, Gupta V et al. Fungal endophthalmitis following cataract surgery: clinical presentation, microbiological spectrum, and outcome. Am. J. Ophthalmol.132(5), 609–617 (2001).
   PubMed Web of Science ®Google Scholar
• Gupta A, Srinivasan R, Kaliaperumal S, Saha I. Post-traumatic fungal endophthalmitis – a prospective study. Eye22(1), 13–17 (2008).
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Flynn HW Jr, Miller D, Scott IU, Alfonso EC. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology115(9), 1501–1507, 1507 e1–2 (2008).
   PubMed Web of Science ®Google Scholar
• Gregori NZ, Flynn HW Jr, Miller D et al. Clinical features, management strategies, and visual acuity outcomes of Candida endophthalmitis following cataract surgery. Ophthalmic. Surg. Lasers Imaging38(5), 378–385 (2007).
   PubMedGoogle Scholar
• Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National Nosocomial Infections Surveillance System. Am. J. Med.91(3B), 86S–89S (1991).
   PubMed Web of Science ®Google Scholar
• Pfaller M, Diekema D. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev.20(1), 133–163 (2007).
   PubMed Web of Science ®Google Scholar
• Essman TF, Flynn HW Jr, Smiddy WE et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg. Lasers28(3), 185–194 (1997).
   PubMedGoogle Scholar
• Rao NA, Hidayat A. A comparative clinicopathologic study of endogenous mycotic endophthalmitis: variations in clinical and histopathologic changes in candidiasis compared to aspergillosis. Trans. Am. Ophthalmol. Soc.98, 183–193; discussion 193–184 (2000).
   PubMedGoogle Scholar
• Tanaka M, Kobayashi Y, Takebayashi H, Kiyokawa M, Qiu H. Analysis of predisposing clinical and laboratory findings for the development of endogenous fungal endophthalmitis. A retrospective 12-year study of 79 eyes of 46 patients. Retina21(3), 203–209 (2001).
   PubMed Web of Science ®Google Scholar
• Brooks RG. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch. Intern. Med.149(10), 2226–2228 (1989).
   PubMedGoogle Scholar
• Donahue SP, Hein E, Sinatra RB. Ocular involvement in children with candidemia. Am. J. Ophthalmol.135(6), 886–887 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Adrian LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. Retinal lesions as clues to disseminated bacterial and candidal infections: frequency, natural history, and etiology. Medicine (Baltimore)82(3), 187–202 (2003).
   PubMed Web of Science ®Google Scholar
• Uzun O, Ascioglu S, Anaissie EJ. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis.32(12), 1713–1717 (2001).
   PubMed Web of Science ®Google Scholar
• Alexandridou A, Reginald AY, Stavrou P, Kirkby GR. Candida endophthalmitis after tattooing in an asplenic patient. Arch. Ophthalmol.120(4), 518–519 (2002).
   PubMedGoogle Scholar
• Sikic J, Vukojevic N, Katusic D, Saric B. Bilateral endogenous Candida endophthalmitis after induced abortion. Croat. Med. J.42(6), 676–678 (2001).
   PubMed Web of Science ®Google Scholar
• Chen SJ, Chung YM, Liu JH. Endogenous Candida endophthalmitis after induced abortion. Am. J. Ophthalmol.125(6), 873–875 (1998).
   PubMed Web of Science ®Google Scholar
• Jabs DA. Ocular manifestations of HIV infection. Trans. Am. Ophthalmol. Soc.93, 623–683 (1995).
   PubMedGoogle Scholar
• Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore)53(1), 47–75 (1974).
   PubMed Web of Science ®Google Scholar
• Krishna R, Amuh D, Lowder CY, Gordon SM, Adal KA, Hall G. Should all patients with candidemia have an ophthalmic examination to rule out ocular candidiasis? Eye14, 30–34 (2000).
   PubMed Web of Science ®Google Scholar
• Samiy N, D’Amico DJ. Endogenous fungal endophthalmitis. Int. Ophthalmol. Clin.36(3), 147–162 (1996).
   PubMedGoogle Scholar
• Sallam A, Lynn W, McCluskey P, Lightman S. Endogenous Candida endophthalmitis. Expert Rev. Anti. Infect. Ther.4(4), 675–685 (2006).
   PubMedGoogle Scholar
• Binder MI, Chua J, Kaiser PK, Procop GW, Isada CM. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore)82(2), 97–105 (2003).
   PubMed Web of Science ®Google Scholar
• Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J et al.Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin. Infect. Dis.27(5), 1130–1133 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang YQ, Wang WJ. Treatment outcomes after pars plana vitrectomy for endogenous endophthalmitis. Retina25(6), 746–750 (2005).
   PubMed Web of Science ®Google Scholar
• Hidalgo JA, Alangaden GJ, Eliott D et al. Fungal endophthalmitis diagnosis by detection of Candida albicans DNA in intraocular fluid by use of a species-specific polymerase chain reaction assay. J. Infect. Dis.181(3), 1198–1201 (2000).
   PubMed Web of Science ®Google Scholar
• Jaeger EE, Carroll NM, Choudhury S et al. Rapid detection and identification of Candida, Aspergillus, and Fusarium species in ocular samples using nested PCR. J. Clin. Microbiol.38(8), 2902–2908 (2000).
   PubMed Web of Science ®Google Scholar
• Tarai B, Gupta A, Ray P, Shivaprakash MR, Chakrabarti A. Polymerase chain reaction for early diagnosis of post-operative fungal endophthalmitis. Indian J. Med. Res.123, 671–678 (2006).
   PubMed Web of Science ®Google Scholar
• Ghosh A, Basu S, Datta H, Chattopadhyay D. Evaluation of polymerase chain reaction-based ribosomal DNA sequencing technique for the diagnosis of mycotic keratitis. Am. J. Ophthalmol.144(3), 396–403 (2007).
   PubMed Web of Science ®Google Scholar
• Takebayashi H, Mizota A, Tanaka M. Relation between stage of endogenous fungal endophthalmitis and prognosis. Graefes Arch. Clin. Exp. Ophthalmol.244, 816–820 (2006).
   PubMed Web of Science ®Google Scholar
• Goldblum D, Fausch K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch. Clin. Exp. Ophthalmol.245(6), 825–833 (2007).
   PubMed Web of Science ®Google Scholar
• Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob. Agents Chemother.46(12), 3719–3723 (2002).
   PubMed Web of Science ®Google Scholar
• Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy27(12), 1711–1721 (2007).
   PubMed Web of Science ®Google Scholar
• Oude Lashof AM, Donnelly JP, Meis JF, van der Meer JW, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur. J. Clin. Microbiol. Infect. Dis.22(1), 43–48 (2003).
   PubMed Web of Science ®Google Scholar
• Manzouri B, Vafidis GC, Wyse RK. Pharmacotherapy of fungal eye infections. Expert Opin. Pharmacother.2(11), 1849–1857 (2001).
   PubMedGoogle Scholar
• O’Day DM, Head WS, Robinson RD, Stern WH, Freeman JM. Intraocular penetration of systemically administered antifungal agents. Curr. Eye Res.4(2), 131–134 (1985).
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother.57(3), 384–410 (2006).
   PubMed Web of Science ®Google Scholar
• O’Day DM, Foulds G, Williams TE, Robinson RD, Allen RH, Head WS. Ocular uptake of fluconazole following oral administration. Arch. Ophthalmol.108(7), 1006–1008 (1990).
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med.331(20), 1325–1330 (1994).
   PubMed Web of Science ®Google Scholar
• Mian UK, Mayers M, Garg Y. Comparison of fluconazole pharmacokinetics in serum, aqueous humor, vitreous humor, and cerebrospinal fluid following a single dose and at steady state. J. Ocul. Pharmacol. Ther.14, 459–471 (1998).
   PubMed Web of Science ®Google Scholar
• Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin. Microbiol. Infect.3(1), 143–144 (1997).
   PubMedGoogle Scholar
• Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica208(3), 147–156 (1994).
   PubMed Web of Science ®Google Scholar
• Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of candidal endophthalmitis. Clin. Infect. Dis.20, 657–664 (1995).
   PubMed Web of Science ®Google Scholar
• Christmas NJ, Smiddy WE. Vitrectomy and systemic fluconazole for treatment of endogenous fungal endophthalmitis. Ophthalmic Surg. Lasers27(12), 1012–1018 (1996).
   PubMedGoogle Scholar
• del Palacio A, Cuetara MS, Ferro M et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses36(5–6), 193–199 (1993).
   PubMed Web of Science ®Google Scholar
• Luttrull JK, Wan WL, Kubak BM, Smith MD, Oster HA. Treatment of ocular fungal infections with oral fluconazole. Am. J. Ophthalmol.119(4), 477–481 (1995).
   PubMed Web of Science ®Google Scholar
• Nomura J, Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin. Infect. Dis.17(5), 888–889 (1993).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect.10(Suppl. 1), 11–23 (2004).
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J. Antimicrob. Chemother.52(4), 679–682 (2003).
   PubMed Web of Science ®Google Scholar
• Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina26(8), 935–939 (2006).
   PubMed Web of Science ®Google Scholar
• Vfend®, prescribing information. Pfizer. NY, USA (2006).
   Google Scholar
• Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia150(3), 101–115 (2001).
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Kuhn DM. Voriconazole – better chances for patients with invasive mycoses. Eur. J. Med. Res.7(5), 242–256 (2002).
   PubMed Web of Science ®Google Scholar
• Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch. Ophthalmol.122(1), 42–47 (2004).
   PubMed Web of Science ®Google Scholar
• Marco F, Pfaller MA, Messer SA, Jones RN. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med. Mycol.36(6), 433–436 (1998).
   PubMed Web of Science ®Google Scholar
• Sabo JA, Abdel-Rahman SM. Voriconazole: a new triazole antifungal. Ann. Pharmacother.34(9), 1032–1043 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis.36(5), 630–637 (2003).
   PubMed Web of Science ®Google Scholar
• Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am. J. Ophthalmol.137(5), 820–825 (2004).
   PubMed Web of Science ®Google Scholar
• Vemulakonda GA, Hariprasad SM, Mieler WF, Prince RA, Shah GK, Van Gelder RN. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch. Ophthalmol.126(1), 18–22 (2008).
   PubMed Web of Science ®Google Scholar
• Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am. J. Ophthalmol.139(1), 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Figueroa MS, Fortun J, Clement A, De Arevalo BF. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina24(2), 319–320 (2004).
   PubMed Web of Science ®Google Scholar
• Garbino J, Ondrusova A, Baglivo E, Lew D, Bouchuiguir-Wafa K, Rohner P. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand. J. Infect. Dis.34(9), 701–703 (2002).
   PubMed Web of Science ®Google Scholar
• Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch. Ophthalmol.121(5), 735–737 (2003).
   PubMedGoogle Scholar
• Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br. J. Ophthalmol.84(8), 932–933 (2000).
   PubMed Web of Science ®Google Scholar
• Scott IU, Cruz-Villegas V, Flynn HW Jr, Miller D. Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am. J. Ophthalmol.137(3), 583–585 (2004).
   PubMed Web of Science ®Google Scholar
• Varma D, Thaker H, Moss P, Wedgwood K, Innes J. Use of voriconazole in Candida retinitis. Eye19, 484–485 (2005).
   Google Scholar
• Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br. J. Ophthalmol.92(7), 871–878 (2008).
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med.347(25), 2020–2029 (2002).
   PubMed Web of Science ®Google Scholar
• Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin. Infect. Dis.40(5), e46–e48 (2005).
   PubMedGoogle Scholar
• Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin. Infect. Dis.41(3), e27–e28 (2005).
   PubMed Web of Science ®Google Scholar
• Baldinger J, Doft BH, Burns SA, Johnson B. Retinal toxicity of amphotericin B in vitrectomised versus non-vitrectomised eyes. Br. J. Ophthalmol.70(9), 657–661 (1986).
   PubMed Web of Science ®Google Scholar
• Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology92(11), 1601–1605 (1985).
   PubMed Web of Science ®Google Scholar
• Dunlap WA, Karacorlu M, Peyman GA, Nair MG, Rahimy M, Pedroza L. Retinal toxicity of intravitreally injected faeriefungin. Ophthalmic Surg.25(5), 303–306 (1994).
   PubMedGoogle Scholar
• Schulman JA, Peyman GA, Dietlein J, Fiscella R. Ocular toxicity of experimental intravitreal itraconazole. Int. Ophthalmol.15(1), 21–24 (1991).
   PubMed Web of Science ®Google Scholar
• Shahsavari M, Peyman GA, Niesman MR. Retinal toxicity and in vitro efficacy study of cilofungin (LY121019). Ophthalmic Surg.21(10), 726–728 (1990).
   PubMedGoogle Scholar
• Yoshizumi MO, Banihashemi AR. Experimental intravitreal ketoconazole in DMSO. Retina8(3), 210–215 (1988).
   PubMed Web of Science ®Google Scholar
• Souri EN, Green WR. Intravitreal amphotericin B toxicity. Am. J. Ophthalmol.78(1), 77–81 (1974).
   PubMed Web of Science ®Google Scholar
• Gao H, Pennesi ME, Shah K et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch. Ophthalmol.122(11), 1687–1692 (2004).
   PubMedGoogle Scholar
• Kernt M, Neubauer A, DE HK, Kampik A. Intravitreal voriconazole: in vitro safety profile for fungal endophthalmitis. Retina29(3), 362–370 (2008).
   Web of Science ®Google Scholar
• Smiddy WE. Treatment outcomes of endogenous fungal endophthalmitis. Curr. Opin. Ophthalmol.9(3), 66–70 (1998).
   PubMedGoogle Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology92(4), 467–471 (1985).
   PubMed Web of Science ®Google Scholar
• Cheng CK, Yang CH, Hsueh PR, Liu CM, Lu HY. Vitrectomy with fluconazole infusion: retinal toxicity, pharmacokinetics, and efficacy in the treatment of experimental candidal endophthalmitis. J. Ocul. Pharmacol. Ther.20(5), 430–438 (2004).
   PubMed Web of Science ®Google Scholar
• Jampol LM, Sung J, Walker JD et al. Choroidal neovascularization secondary to Candida albicans chorioretinitis. Am. J. Ophthalmol.121(6), 643–649 (1996).
   PubMed Web of Science ®Google Scholar